BMS buys Mirati for $4.8B; Pfizer to slash cost; Q&A with Vertex CSO; Alnylam’s Onpattro setback; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Af­ter Mi­rati opened the week with a multi­bil­lion-dol­lar buy­out, we take a look at Bris­tol My­ers Squibb’s bud­ding ri­val­ry with Am­gen, Pfiz­er’s planned cost cuts, a sur­prise CRL for Al­ny­lam, a busy stream of clin­i­cal read­outs and much, much more. Don’t miss our roundup of the key take­aways from our #Eu­ro­Bio23 sum­mit in Lon­don.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.